ENOCHIAN BIOSCIENCES INC

$2.77 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About ENOCHIAN BIOSCIENCES INC

Enochian BioSciences Inc. is a pre-clinical stage biotechnology company. The Company uses its cell, gene and immune therapy technologies for the treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, as well as to provide cancer remission in some of the deadliest cancers. The Company’s product candidates include ENOB-HV-01, an autologous transplant with genetically modified cells; ENOB-HV-11 and ENOB-HV-12, preventive and therapeutic vaccines; ENOB-HV-21, immunotherapy with allogeneic NK/GDT cells; ENOB-HV-31, in Vivo gene therapy; ENOB-HB-01, potential cure for HBV; ENOB-CV-01, Aerosol/Inhaled treatment potentially for all Coronaviruses that cause human disease; ENOB-CV-11, Aerosol/Inhaled prophylaxis potentially for all coronaviruses that cause human disease; ENOB-FL-01 Aerosol/Inhaled treatment potentially for all influenza viruses; and ENOB-FL-11, Aerosol/Inhaled prophylaxis potentially for all influenza viruses.

Stock Analysis

last close $2.77
1-mo return 36.5%
3-mo return -56.7%
avg daily vol. 96.95T
52-week high 13.78
52-week low 1.42
market cap. $147M
forward pe -
annual div. -
roe -25.1%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 6.8%
baraka

Subscribe now for daily local and international financial news

Subscribe